Podcasts about phase ii

Some of the most exciting science in our Solar System is hidden in places we've never been able to reach. In this episode, Sarah Al-Ahmed shares three conversations from the 2026 NASA Innovative Advanced Concepts (NIAC)Symposium at Wichita State University, all about the bold, early-stage concepts being developed to explore them. First, Peter Cabauy, CEO and co-founder of City Labs Incorporated, and Mason Peck, former NASA Chief Technologist and collaborator on the project, discuss their Phase II concept, Autonomous Tritium Micropowered Sensors, tiny nuclear-powered probes designed to survive and operate in the permanently shadowed craters of the Moon and beyond. Then, Daniel Drew, assistant professor of electrical and computer engineering at the University of Hawaiʻi at Mānoa, introduces SPARK, a Phase I concept for silent, solid-state flying robots that could explore caves on Saturn's moon Titan. Finally, Gilly Elor, physics lead at Stone Aerospace, and Bill Stone, founder of Stone Aerospace, walk us through LUX, the Lunar Underground Explorer, a Phase I concept for a laser-powered, fiber-tethered drone that could be the first mission to enter a cave on another world. Plus, Bruce Betts, chief scientist of The Planetary Society, joins Sarah for What's Up, where they preview Saturn at opposition and the start of World Space Week on October 4th. Discover more at: https://www.planetary.org/planetary-radio/2026-niac-symposium-part-1 See omnystudio.com/listener for privacy information.

Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics: Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00) Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09) Key findings from the Phase III ROSELLA study (7:06) Case: A woman in her early 50s with FIGO Stage IVB platinum-ineligible high-grade serous carcinoma of the fallopian tube enrolls in the Phase III ROSELLA study (15:02) Case: A woman in her late 40s with FIGO Stage IIIB platinum-ineligible high-grade serous ovarian carcinoma enrolls in the Phase II BELLA trial (23:42) CME information and select publications

Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02) Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25) Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43) Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications

There is an urgent need for safe and effective therapies to improve outcomes for patients with relapsed osteosarcoma. Viscum album extract (Iscador P, Iscador AG, Arlesheim, Switzerland) is a mistletoe extract manufactured from the leaves, stems and berries of Viscum album L., grown on pine trees (P = Pini). It has shown efficacy and safety in lab experiments and small clinical trials for patients with relapsed osteosarcoma. Data from a small pilot study in Italy paved the way for developing a larger clinical trial in the United States to test the use of Viscum album extract for children, teenagers, and young adults with osteosarcoma that has come back and can be removed with surgery. Another goal of this study is to learn more about what impact Viscum Album extract may have on patients' quality of life, tumor biology and immune system during treatment.

Welcome to the Atomic Anesthesia podcast hosted by CRNA professor Dr. Rhea Temmermand and Co-Founder Sachi Lord. On this show, you'll hear clear, clinically grounded discussions designed for nurse anesthesia residents and CRNAs who want to feel more confident in complex pharmacology, physiology, and real-world anesthesia decision-making.Want more content like this? Become a member of our learning platform: http://atomicanesthesia.comIn this episode:Train-of-four basics, including what the twitches actually represent and how to interpret your TOF countTOF count vs TOF ratio, understanding fade, and why four twitches does not necessarily mean full recoveryPost-tetanic count, depth of neuromuscular blockade, and when to use different stimulation patternsUlnar vs facial nerve monitoring, Phase I vs Phase II succinylcholine blockade, and qualitative vs quantitative monitoringUsing TOF to guide neostigmine and sugammadex reversal, plus high-yield SEE/NCE concepts and practice board questions

Interview with Thomas Lamb, CEO of Myriad Uranium Corp.Our previous interview: https://www.cruxinvestor.com/posts/made-in-america-myriad-uranium-csem-americas-uranium-gap-the-wyoming-project-closing-it-10614Recording date: 16th September 2026Myriad Uranium Corp. (CSE:M) is a US-focused uranium exploration company whose flagship asset, the Copper Mountain Uranium Project in Fremont County, Wyoming, carries one of the largest historical uranium resource bases in the country. The project was extensively drilled in the 1970s by Union Pacific which delineated seven deposits and designed a conventional six-pit mine plan before uranium prices collapsed following the Three Mile Island incident in 1979. Those historical efforts left behind a resource estimate of 26.63 Mlbs eU₃O₈ in 48.95 Mt at 269 ppm, and a separate 1982 U.S. Department of Energy-commissioned study (Bendix Field Engineering) identified an exploration target of up to 655 Mlbs across a wider assessment area. Neither figure is a current, NI 43-101-compliant mineral resource, and Myriad is careful to flag both as historical and, in the case of the exploration target, conceptual.Myriad has spent the past two years re-testing that legacy. A 34-hole Phase I programme at the Canning deposit, completed in November 2025, found that modern laboratory assays consistently outperformed the historical gamma-probe grades - by 20% at a 200 ppm cut-off, rising to 60% at 1,000 ppm - a pattern the company attributes to radiometric disequilibrium not captured by 1970s-era probe technology alone. That result underpins the current Phase II programme, a roughly 5,000-metre, two-stage effort launched in July 2026 and funded from the company's own cash position (approximately $10 million against a budgeted $6 million spend). Stage 1 is retesting the historic deposits - Gem, Hesitation, Arrowhead, Mint and continued work at Canning - while Stage 2 is testing new ground identified through district-wide radiometric and magnetic surveying, including the Lucky Cliff prospect, where four holes returned 50 mineralised intervals above 100 ppm eU₃O₈ entirely outside the historic resource footprint.Corporately, Myriad consolidated 100% ownership of Copper Mountain in August 2026 via merger with Rush Rare Metals Corp - the first time the district has had a single owner in nearly 50 years - and is preparing a NASDAQ or NYSE American listing application, described as roughly 80% complete. The company also holds a 23-target breccia pipe exploration portfolio on the Arizona Strip near Energy Fuels' high-grade Pinyon Plain Mine, optioned to Wedgemount Resources on a partner-funded earn-in structure, and retains a 10% free carried interest plus a strategic alliance in the Red Basin Project in New Mexico, sold in May 2026 to technology-investor-backed Subatomic for a better-than-6x cash-on-cash return.As of September 2026, Myriad had approximately 140.1 million shares outstanding (195.0 million fully diluted) and a market capitalisation near C$67.3 million, with no reported short interest. CEO Thomas Lamb has framed the company's capital approach around avoiding the fate of peers that funded large resource-confirmation drilling programmes without a corresponding re-rating, positioning Copper Mountain's next drill results due through the remainder of Phase II as the key near-term catalyst for the stock.Learn more: https://www.cruxinvestor.com/companies/myriad-uraniumSign up for Crux Investor: https://cruxinvestor.com/subscribe

In this Supplement Stack Series episode, Nurse Doza breaks down the MTHFR gene — the enzyme behind methylation, detoxification, neurotransmitter production, and energy — and explains why the form of folate you take matters if you carry one of the common variants. He walks through The MTHFR Stack by MSW Nutrition: the methyl donors, the methylated B vitamins, and the liver support that keep the methylation cycle turning. If methylation is your bottleneck, start here. FEATURED PRODUCT The MTHFR Stack by MSW Nutrition bundles the three formulas Nurse Doza reaches for when methylation support is the goal — Bliss, Boost, and Liver Boost — into one system. Together they cover the methyl donors (betaine/TMG and SAMe), the methylated B vitamins (methylfolate, methylcobalamin, B6 as P-5-P) and glutathione, and the phase II liver pathway where methylation and detoxification meet. Rather than supporting one step and starving the next, the stack works the whole cycle.

DAVE LEE – REMIXOLOGY WEEK 2 In the final instalment of our Dave Lee Remixology special, we dive further into the aliases, remixes and productions that shaped his 35‑year legacy — from Joey Negro classics to Jakatta and Raven Maize gems. We trace the sound that bridged disco, soul, funk and house for generations of clubbers, celebrating a producer whose passion for disco never faded. FASCINATED Raven Maize 2002 MY VISION Jakatta feat. Seal 2003 DESIRE Ultra Nate 2000 Joey Negro Z Remix LET YOURSELF GO Frankie Knuckles feat. Sybil 2020 Joey Negro Club Mix IN YOUR ARMS (WE GONNA MAKE IT) Benjamin Diamond 2000 Joey Negro Z Mix MAKE A MOVE ON ME Joey Negro feat. Taka Boom 2006 GYPSY WOMAN (SHE’S HOMELESS) Crystal Waters 1992 Joey Negro’s Mindmix SECRET LOVE Danni’elle Gaha 1993 Joey Negro’s Masta Mix TEARDROPS Lovestation 1998 Joey Negro Edit REACHIN’ Phase II 1991 Negro’s Radio Version MOVE ME NO MOUNTAIN Soul II Soul 1992 Removed Club Mix The post TTBA Replay 11SEP2026 Pt. 2 appeared first on Turn the Beat Around.

Send us Fan MailNew construction is supposed to feel like a fresh start, but what if the “new house smell” is a warning sign? We are Jim and Laura, and we have been inspecting newer homes that look spotless on the surface yet still come with real indoor air quality problems, including mold concerns and chemical exposure that sends homeowners searching for VOC testing and formaldehyde testing. When people feel sick at home, they are often shocked to learn the issue is not just an old-house problem.We dig into the part almost nobody budgets time for: the land beneath the house. In Ohio, many developments are built on former farmland, and that history can include legacy pesticides, stored fuels, and other contaminants that do not disappear just because the neighborhood is brand new. Layer modern building materials and tight construction on top of that, and you can end up living with a mix of off-gassing and environmental residue day after day.We also break down the most practical tool for buyers who want facts before they sign: the Phase I Environmental Site Assessment, plus when a Phase II investigation is needed to take real samples of soil, soil gas, or water. We talk about why banks and lenders often require Phase I reports for commercial deals, why single-family builds may not be forced to do it, and how that gap can leave families taking on hidden risk. If you are building a home, buying in a new subdivision, or planning a final walkthrough or 11-month warranty inspection, this is your checklist for smarter due diligence. Subscribe, share this with a friend shopping for a new build, and leave a review with the biggest question you still have about land history and healthy homes.Support the showTo learn more about Habitation Investigation, the Three-time Winner of the Best Home Inspection Company in the Midwest Plus the Winner of Consumer Choice Award for Columbus Ohio visit Home Inspection Columbus Ohio - Habitation Investigation (homeinspectionsinohio.com) NBC4 news segments: The importance of home inspections, and what to look for | NBC4 WCMH-TVAdvice from experts: Don't skip the home inspection | NBC4 WCMH-TVOSU student's mysterious symptoms end up tied to apartment's air quality | NBC4 WCMH-TVHow to save money by winterizing your home | NBC4 WCMH-TVContinuing Education for Ohio Agents Scheduled classes Continuing Education for Ohio Agents Course listings...

Alex Langer, President and CEO of Sierra Madre Gold And Silver (TSXV: SM) (OTCQX: SMDRF), joins me to recap the Q2 operations and financial update at the La Guitarra silver-gold mine complex in Mexico, which includes 3 producing mines:  La Guitarra, Coloso, and Nazareno.   We look ahead to the 2-phase mill expansion and upcoming increased 30,000 meters of drilling planned across the La Guitarra District.  Additionally, we discussed the path forward at the recently acquired Del Toro mining complex, and the increased drill program to 30,000+ meters of drilling at the property starting in the second half of this year.   Q2 2026 Highlights   Revenues: Silver revenues for the quarter totaled $5.0 million ($75.65 per ounce) and gold revenues totaled $4.3 million ($4,529 per ounce). Silver revenues for the quarter ended June 30, 2025 ("Q2 2025"), totaled $2.2 million ($33.36 per ounce) and gold revenues totaled $3.6 million ($3,272 per ounce). Adjusted EBITDA of $3.5 million for the six months ended June 30, 2026 ("H1 2026") compares to $2.6 million for the six months ended June 30, 2025 ("H1 2025"). Gross Profit was $1.58 million for Q2 2026, as compared to $1.69 million for Q2 2025. Cash from Operations: the Company generated $1.89 million of cash from operating activities in H1 2026 as compared to $1.37 million in H1 2025. Cash and Cash Equivalents at June 30, 2026 totaled $22.2 million, with $25.0 million in working capital, compared to $13.2 million and $14.4 million at March 31, 2026, respectively. Daily Production is now reaching up to 672 tonnes per day ("tpd"), a 34% increase over the previous level of 500 tpd. Del Toro Acquisition: Following shareholder approval (April 28, 2026 news release) and Mexican Antitrust approval (announced May 22, 2026), the Company closed the acquisition of a 100% interest in the Del Toro silver mine, as announced on June 22, 2026. With this acquisition, Sierra Madre completed a concurrent financing for gross proceeds of CAD$57.5 million. Geologic mapping and sampling have started at Del Toro with a re-evaluation of surveys underway and drilling expected to start in mid-2027. East District Exploration: Following quarter-end, as released on July 14, 2026, Sierra Madre received approval to start drilling in the East District of the Guitarra complex. Target definition work is underway with drilling bids in hand for a long-hole sub-horizontal drill program planned from the Tlacotal property (a permitted area designated for mining). Drilling is expected to start in H2 2026. First Majestic Loan Repayment: As announced on July 8, 2026, the Company has fully repaid the US$5 million non-revolving, secured term loan with First Majestic Silver. Operational Details Production: Ahead of the Phase I and II expansion plans, Sierra Madre selected a contractor to ramp up production from the higher-grade Coloso and Nazareno mines; contractor operations started mid-June. Sierra Madre miners and equipment are now focused on accelerating production at the Guitarra mine. Costs: The Q2 2026 cash costs were negatively impacted by the ramp up and development work at Coloso and Nazareno, leading to a significant share of production being sourced from development drives and out-of-resource, lower grade mineralization. While adding to top-line revenues, increased commodity prices also add to our cash costs through increased royalty payments and taxes. The strengthening Mexican peso against the US dollar, inflation impacts on inputs, and rising worker pay rates also affected costs. Recoveries: Gold and silver recoveries declined as the ongoing development work opened new mining areas and resulted in a blend of feed from three mining centres. Sierra Madre has built a metallurgical lab at the site to optimize the blending protocol. Power Generation: In Q2 2026, power outages continued due to weather incidents, increasing costs. Sierra Madre acquired a 1,250-kilowatt ("kW") back-up diesel generator for Coloso and Nazareno (installation is underway), plus two 1,500-kW back-up diesel generators for the plant. Installation of the two Guitarra generators was completed mid-August 2026 and are expected to be fully operational in September. Equipment: The transfer of a narrow-profile Muki jumbo drill to the Guitarra mine is expected to support development and production of narrower and higher-grade veins in the San Raphael area and of the Juliet vein. Following quarter end, the rebuild of a 0.5-yard scoop tram has reduced dilution and mining costs for the Juliet vein. Sierra Madre also purchased two haul trucks in April, to replace rental units used in the tailings buttress program and for Coloso haulage, which are expected to lead to cost reductions. Two scoops were also acquired to support increased mining rates with the expansion. Coloso and Nazareno: Mining restarted at the higher-grade Coloso underground mine at the end of Q1 2025 (estimated resource grades at Coloso are significantly higher in both silver and gold compared to the Guitarra mine veins[1]). In September 2025, Sierra Madre also announced the restart of mining at the Nazareno mine. At Coloso, dewatering of the lower levels has been accelerated and production from resource blocks below the existing workings is expected to start in the second half of 2026. Nazareno began full production from long-hole stopes on the 180 level in late April 2026. Expansion Progress As announced on September 8, 2025, the Company has initiated a plan to expand production capacity at Guitarra in a two-phase program with the first phase aimed at increasing the nameplate capacity of the mill from 500 tpd to a range of 750-800 tpd. The second phase is anticipated to be completed by Q3 2027, with the aim of increasing the capacity to a range of 1,200-1,500 tpd at Guitarra. With the larger-than-planned mill purchased for Phase I, additional foundation and electrical work was required - Sierra Madre now anticipates achieving Phase 1 production capacity before the end of Q3 2026. The purchase of this larger mill has moved the completion of this aspect of the Phase II expansion ahead of schedule. Since the end of Q2 2026, foundation work has been completed for the ball mill, support equipment, and building enclosure, with an overhead crane installed. Modifications to the existing mill and the installation of larger capacity pumps resulted in an increased total mill throughput capacity: daily production is now reaching up to 672 tpd, a 34% increase over the previous level of 500 tpd. Refurbishment of the used ball mill, purchased in December 2025, was completed at the end of Q1 2026, increasing its rated milling capacity to 900 tpd. A standard head crusher, purchased in Q4 2025, started full operation in April 2026 (two months ahead of schedule). Together with modifications to the primary crusher, this addition is expected to allow the circuit to surpass the Phase I objective of 750-800 tpd. Thickener tank construction was completed in mid-August 2026, with testing of the mechanical and electrical circuits underway - the thickener is expected to be functional by the end of September. Shipping delays pushed back completion from the original late June 2026 estimate. The thickener is designed to thicken tailings to ±60% solids, allowing a significant portion of the tailings to be pumped directly to open stopes below the main San Raphael mine level, using existing tailings pumping equipment. Sierra Madre has also chosen to proceed with the construction of the new permitted dry stack tailings storage facility. Site clearing is expected to start in October. Construction of a filter plant and a second thickener will also be needed for the Phase II expansion.   If you have any questions for Alex regarding Sierra Madre Gold and Silver, then please email them to me at either Shad@kereport.com.   In full disclosure, Shad is a shareholder of Sierra Madre Gold and Silver and may choose to buy or sell shares at any time.   Click here to follow along with the latest news from Sierra Madre Gold & Silver     For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.        

This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies Inc. (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger Dumoulin-White, B.Sc, P. Eng. discusses the company's clinical-stage cancer treatment technology and its development for patients with BCG-unresponsive non-muscle invasive bladder cancer. The interview covers interim Phase II clinical study results for Ruvidar®, including response durability and safety, as well as the potential advantages of Theralase's drug and proprietary light activation system.Learn more: https://theralase.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=sb-_w3PoR_kAnd follow us to stay updated: https://www.youtube.com/@stockstowatchofficial 

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the acquisition of CRS Berlin and how the clinical trial unit will expand hVIVO's early drug development platform, therapeutic expertise and presence in Germany. CRS Berlin is a Phase I and Phase II clinical trial unit with experience across more than 300 trials, with particular strength in dermatology and women's health and a track record working with biotech and mid-sized pharma companies. The business brings an order book of just under €10 million and is expected to be earnings accretive for full year 2026. Khan said the deal complements hVIVO's existing work in cardiometabolic, respiratory and infectious disease, adding two further therapeutic areas. On women's health, he noted women have historically been underrepresented in early clinical research, an area he expects hVIVO to grow. The acquisition also boosts capacity for larger Phase II trials and gives access to a potential patient population of around six million in metropolitan Berlin. "For us, it does create new markets as well as giving us new cross-selling opportunities," Khan said. Integration is expected to be straightforward given hVIVO's existing close ties to CRS Berlin following its earlier acquisitions of CRS Kiel and CRS Mannheim, with shared patient recruitment, back-office and project management functions already in place. On deal structure, Khan said a nominal upfront payment with the remainder linked to a three-year revenue-based earn-out allows hVIVO to add capacity and growth opportunities while maintaining a strong balance sheet. Visit Proactive's YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #hVIVO #HVO #CRSBerlin #ClinicalTrials #ClinicalResearch #Biotech #Pharma #DrugDevelopment #WomensHealth #Dermatology #Phase1Trials #Phase2Trials #CRO #LifeSciences #Proactive

Interview with Keith Henderson, President & CEO of Latin MetalsOur previous interview: https://www.cruxinvestor.com/posts/latin-metals-tsxvlms-the-prospect-generator-model-few-juniors-follow-10250Recording date: 14th August 20206Latin Metals Inc. (TSXV:LMS) has added a third active partner-funded project to its portfolio with an ongoing agreement with Minsur, a private Peruvian mining company already in a 75/25 joint venture with Newmont on adjacent ground to cover the Lacsha copper-molybdenum porphyry project in southern Peru.Under the deal outlined by CEO Keith Henderson, Minsur can earn an initial 75% interest in Lacsha by completing 60,000 metres of drilling over six years and paying Latin Metals approximately $2.5 million in cash, a commitment Henderson estimated at roughly C$40 million in Minsur-funded exploration spending. Once that threshold is met, Minsur holds a time-limited option to acquire the remaining 25% for C$28 million which would leave Latin Metals with a 2% net smelter return royalty. Minsur separately holds a three-year option to buy 1% of that royalty for a further $20 million. Combined, Henderson said, the structure could deliver a little over $42 million in cash coming into the company.Latin Metals generated Lacsha internally, spending approximately $900,000 (CAD) on staking, mapping, geochemistry and geophysics before bringing in a partner - notably more than the company's typical $200,000-$300,000 generative budget per project, which Henderson attributed to years of incremental exploration work culminating in a stronger-than-usual technical package. Lacsha's location directly south of Minsur's existing Newmont joint venture ground gives the new partner a clear strategic rationale to test the structural and geochemical extension onto Latin Metals' claims.The Lacsha deal brings Latin Metals' total under-contract partner investment to approximately $120 million, spanning Lacsha, Cerro Bayo and La Flora (Daura Gold), and Zaha (Moxico Resources), all funded externally against a corporate budget Henderson described as flat at $3 million per year. Management is targeting further deals across the remaining pipeline including Organullo, Crosby and an Argentine sediment-hosted copper package during 2026, which it expects could push cumulative under-contract investment toward $150-180 million.Near-term catalysts sit with the Argentine silver-gold assets rather than Lacsha itself: Daura Gold's Phase II drill programme at Cerro Bayo is scheduled for Q3 2026, alongside the first drill test of the high-grade La Flora vein system, where surface sampling has returned grades as high as 82 g/t gold and 1,239 g/t silver historically. Combined partner-funded drilling across the portfolio is expected to reach approximately 18,000 metres in 2026.On financing, Henderson said Latin Metals expects roughly C$1.8 million from warrant exercises in September 2026, with warrants priced at 15 cents against a share price near 25 cents, a gap management is relying on to avoid raising additional equity capital through 2026 and 2027. As with all early-stage option structures, the eventual scale of Lacsha's payoff depends on drill results Latin Metals will not itself control, since the company does not intend to operate the project once Minsur's drilling begins.View Latin Metals' company profile: https://www.cruxinvestor.com/companies/latin-metalsSign up for Crux Investor: https://cruxinvestor.com

This interview is disseminated on behalf of Eastport Critical Metals Corp.Eastport Critical Metals (TSXV: EVI | OTCQB: EVIIF) CEO Daniel Major joins us to discuss the Phase II soil sampling results from the Selebi East Project in Botswana.Major explains the significance of multi-kilometre nickel-copper soil anomalies associated with amphibolite host rocks. He also outlines Eastport's planned next steps, including further geophysical work followed by drilling, as the company advances exploration across its Botswana portfolio.Learn more: https://eastportcmc.comWatch the full YouTube interview here: https://youtu.be/rKnn1tgsydk?si=joY2KAs_MCRXTuIrAnd follow us to stay updated: https://www.youtube.com/@stockstowatchofficial 

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8)Draganfly signed an exclusive strategic partnership with the Small & Rural Law Enforcement Executives Association (SRLEEA) to launch a Drone Implementation & Readiness Program for small, rural, and tribal law enforcement agencies. The program bundles policy development, FAA Part 107 training, and Draganfly drone platforms into one member service aimed at agencies that represent more than 90% of U.S. law enforcement. It positions Draganfly as a go-to drone supplier and training partner for a large, underserved public-safety market.Renforth Resources Inc. (CSE: RFR) (OTC: RFHRF) (FSE: 9RR)Renforth completed its drill program at the wholly owned Victoria nickel-copper-cobalt deposit, hitting visual mineralization in all three holes and extending mineralization down dip beyond the current resource. A prior undercut hole assayed 170.55 metres of 0.16% nickel, including 1.5 metres of 3.46% nickel. Assays on the new holes are pending, and success could grow the Victoria polymetallic deposit alongside Renforth's flagship Parbec gold project.Spanish Mountain Gold Ltd. (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF)Spanish Mountain Gold reported strong feasibility-stage drill results, highlighted by 252.3 metres of 0.82 g/t gold, including 93.5 metres of 1.32 g/t gold. With about 18,500 metres of a planned 60,000 metre program complete and 16 holes still pending, the results support the infill and expansion goals of a feasibility study targeted for early 2028. The company is fully funded following a US$55 million royalty sale to Wheaton Precious Metals.Rock Tech Lithium Inc. (TSX-V: RCK) (OTCQX: RCKTF)Rock Tech signed a binding long-term spodumene offtake agreement with Geneva-based trading house Transamine SA for its Georgia Lake project in Ontario, securing a development prepayment facility of up to US$80 million. The seven-year deal, starting in 2028, covers up to 100,000 dry metric tonnes per year and can convert into battery-grade lithium chemicals through the planned Red Rock Converter. The agreement strengthens financing and offtake certainty for the company's integrated Ontario supply chain.Silver Elephant Mining Corp. (TSX: ELEF) (OTCQB: SILEF) (FSE: 1P2)Silver Elephant reported new high-grade results from its Apuradita silver project in Bolivia, with channel sampling returning 539 g/t silver over 10 metres. The company also produced a third silver concentrate batch of roughly 32 tonnes grading 12,168 g/t silver and 32.75% lead, and plans monthly production of 400 to 600 tonnes through 2027. Barksdale Resources Corp. (TSXV: BRO) (OTCQB: BRKCF) (FSE: 2NZ)Barksdale exceeded the 25,000-foot drilling requirement to advance its Phase II earn-in on the Sunnyside copper project, clearing the way to increase ownership to 67.5%. Power Metals Corp. (TSXV: PWM) (FRANKFURT: OAA1) (OTCQB: PWRMF)Power Metals signed a non-binding MOU with APL Engineered Materials, a leading North American cesium chemicals producer, to develop an integrated cesium supply chain for U.S. markets. The partnership targets aerospace, defence, medical imaging, and electronics applications as global cesium supply tightens. Axo Metals Corp. (TSXV: AXO)Axo Metals received a positive environmental impact decision (MIA) from Mexico's SEMARNAT for its San Antonio gold project in Sonora, the primary authorization required to build and operate the mine. Bottom Line: Today's small-cap news was led by strong drill and sampling results in gold, silver, and copper, alongside major financing and offtake deals in lithium and royalties, plus key regulatory and commercial milestones across mining and technology. Stay ahead of the market — follow AGORACOM for more breaking small-cap news and insights.

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Element 29 Resources Inc. (TSXV: ECU) (OTCQB: EMTRF) (BVL: ECU)Drill hole ELID035 at the Elida copper-molybdenum-silver porphyry in Peru returned 1,534.6 metres grading 0.58% copper-equivalent, the company's longest continuous intercept to date and extending mineralization more than 1,000 metres beyond the current resource. With two rigs active and about 4,885 metres drilled of a planned 10,000-metre program, the results reinforce the scale and depth of the system. For investors, the hit signals meaningful room for future resource expansion at one of Peru's larger undeveloped copper deposits.Canada Nickel Company Inc. (TSX-V: CNC) (OTCQB: CNIKF)Canada Nickel delivered an initial mineral resource at its Nesbitt project and a 46% increase in indicated resources at Deloro, completing its ninth deposit across the Timmins Nickel District. The district now hosts 4.36 billion tonnes of measured and indicated resources at 0.24% nickel, containing over 10 million tonnes of contained nickel. The milestone underscores the district-scale potential of the Ontario nickel portfolio as the company works toward a preliminary economic assessment.Aclara Resources Inc. (TSX: ARA)Aclara was selected by the U.S. Department of Energy for federal funding under its Genesis Mission initiative to apply artificial intelligence to heavy rare earth separation. The Phase I project, run with Argonne National Laboratory and Virginia Tech, aims to optimize domestic rare earth processing, with successful projects eligible to advance to Phase II for additional funding. The award validates Aclara's strategy of building a secure rare earth supply chain across the Americas and ties it to a national critical-minerals priority.Fitzroy Minerals Inc. (TSXV: FTZ) (OTCQX: FTZFF) (FSE: C3Y)Fitzroy intersected 111.9 metres at 0.97% copper from 21.1 metres, including 18.0 metres at 1.59% copper, at its Buen Retiro project in Chile. The company has four rigs turning and aims to complete the drill-out of the newly named Tenorita area in August to support a planned pre-feasibility study and targeted production in early 2028. The wide, shallow copper hits strengthen the case for a low-strip, near-surface open-pit operation.Kirkland Lake Discoveries Corp. (TSXV: KLDC) (OTCQB: KLKLF)Kirkland Lake Discoveries expanded its Mirado gold system with 18.99 g/t gold over 6.7 metres and a broad 0.50 g/t gold over 91.0 metres, while extending the North Zone by about 85 metres. A first regional hole 500 metres west at the MZ Zone hit intense alteration and sulphides, suggesting the mineralized corridor may reach beyond the historical deposit. With a regional drill permit secured and 16 holes awaiting assays, the company has multiple near-term catalysts across its KL South property.Troilus Mining Corp. (TSX: TLG) (OTCQX: CHXMF) (FSE: CM5)Troilus drilled 1.10 g/t gold-equivalent over 103 metres, including 2.10 g/t over 34 metres, from inferred material within the Z87 reserve pit at its Quebec project. The optimization program is converting previously unsampled or waste-classified rock into potential ore, which management expects to improve early-year mill feed and lower strip ratios. The results support ongoing efforts to strengthen the mine plan for the feasibility-stage former Troilus mine.Scorpio Gold Corporation (TSXV: SGN) (OTCQB: SRCRF) (FSE: RY9)Scorpio Gold closed an upsized public offering for gross proceeds of $10.8 million, issuing 43.2 million shares at $0.25 each. Atlas Salt Inc. (TSXV: SALT) (OTCQX: SALQF) (FSE: 9D00)Atlas Salt received a non-binding letter of interest from Export Development Canada for up to C$150 million in long-term debt for its Great Atlantic Salt Project in Newfoundland.

This special edition covers the Pentagon's recent suspension of Cybersecurity Maturity Model Certification (CMMC) Phase II requirements and initiation of a 60-day review by the CMMC Reform Task Force, and is hosted by Yuan Zhou, Kate Growley, and Nkechi Kanu. Crowell & Moring's "Fastest 5 Minutes" is a biweekly podcast that provides a brief summary of significant government contracts legal and regulatory developments that no government contracts lawyer or executive should be without.

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Show Notes: https://securityweekly.com/esw-468

Interview with Keith Hollender, CEO and Co-Founder of Arcova Why AI Security Is Becoming an Execution Problem, Not Just a Governance Problem As enterprises move from AI experimentation to adoption at scale, security leaders are under pressure to enable innovation without introducing unmanaged risk. The challenge is no longer whether organizations should pursue AI, but how they can govern it, secure it, and operationalize it in ways that stand up to real-world business and threat conditions. In this conversation, Keith Hollender discusses what Arcova is seeing across enterprise environments as organizations work to connect cybersecurity, AI governance, resilience, and broader transformation priorities. He explores where companies are getting stuck, why traditional siloed approaches are falling short, and what it takes to move from strategy decks to secure execution. Keith also shares how Arcova's practitioner-led, relationship-driven model helps organizations turn complexity into clarity by embedding with client teams, solving urgent problems hands-on, and building capabilities designed to last. The conversation also covers Arcova's continued growth, including expansion into the Middle East, and what global demand signals reveal about the next phase of cybersecurity and AI consulting. Segment Resources: https://arcova.com/sectors/ https://arcova.com/category/blog/ For more information about Arcova and how they can help your enterprise shape what's next, please visit: https://securityweekly.com/arcova Topic: CMMC Pause creating chaos among federal contractors This one sent some shockwaves through the CMMC community, particularly the hundreds or thousands of folks gearing up to assist with the validation that phase 2 aimed to provide. The TL;DR - defense contractors have been required to comply with CMMC controls for years, but self-attestation means that many probably haven't been meeting the requirements. Perhaps, rather than have tons of defense contractors fail the test, they just suspended the requirement for the test itself. I think Howard Holton nails it here when he says: "100,000 defense contractors needed third-party assessments. Roughly 100 authorized assessors exist. That's 1,000 assessments each, with the deadline in November." PCI already created a model that works for a scenario like this. If you're small, you self-assess. If you're big enough, an independent auditor comes to check you out once a year. I'm sure they were probably aware of this and chose not to go down that path for some reasons. I'm not aware of those reasons. What this means: Phase II is paused Phase I self-assessments still in place (note, however, that phase II existed, because self-attestation didn't work) NIST SP 800-171 Rev 2 and DFARS 252.204-7012 compliance still required 60-day review aims to reform CMMC DoW opened an RFI for industry perspectives on what they should do CMMC characterized as a "compliance burden" and "red tape" False Claims Act and DOJ's cyber-fraud enforcement are still on the table More resources: CIO Davies' post on Twitter Administrator of the Small Business Administration, Kelly Loeffler's post A useful LinkedIn post that breaks down a lot of what this really means (and doesn't) Weekly Enterprise News Finally, in the enterprise security news, will AI eliminate more cybersecurity jobs than it creates? Linus's law, amended the biggest patch Tuesday ever AI context bombs AI workflows are a security disaster people using AI in areas they don't understand ransomware crews are hitting legal firms hard lessons learned from CISA's recent github leak demystify your USB cables! All that and more, on this episode of Enterprise Security Weekly. Show Notes: https://securityweekly.com/esw-468

Pentagon suspends CMMC Phase II requirements US troop location data under attack in Iran "Context Bombing" flips the script on prompt injections Get the show notes here: https://cisoseries.com/cybersecurity-news-cmmc-phase-ii-suspended-tracking-troops-in-iran-defenders-turn-to-context-bombing/  Huge thanks to our sponsor, ThreatLocker Every security leader is being asked the same question right now: How do we enable innovation without creating unnecessary risk? That's the challenge behind cloud adoption. Behind AI. Behind automation. And behind every major technology decision. ThreatLocker helps organizations take a Zero Trust approach to that challenge—giving them greater control over what can execute, what can access their environment, and what users and applications are allowed to do. That's why ThreatLocker is proud to support Cyber Security Headlines. Because security works best when innovation and control move together.

This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001.The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investmentDisclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Flintco has been building Arkansas since 1951, and we took Flintco Talks on the road to Bentonville to celebrate 75 years of construction. We sat down with Scott Eccleston, President of Campus Planning and Facility Management for Art and Wellness Enterprises, Alice Walton's Bentonville-based cultural and wellness organization, and Flintco Construction Director Jesse Evans and Vice President Patrick Horrath, both based in Northwest Arkansas. You'll hear Scott's behind-the-scenes stories of a four-hour job interview with Alice Walton, crews working through the night to beat a museum opening, and an architect visibly moved by what the team built.The conversation covers a lot of ground. Scott shares how a walk through the woods with his three boys on what would become the site of Crystal Bridges and a late-night phone call from world-renowned architect Moshe Safdie set the course for the second half of his career. Jesse and Patrick relive some of the challenges they overcame delivering Phase II of Crystal Bridges on a site straddling a floodway, with controlled blasting within 80 feet of priceless artwork and a meticulous architect watching every pour of exposed concrete.They also talk about what's next. Art and Wellness Enterprises is developing a healthcare campus in Bentonville with a vision that has grown well beyond its original scope, and Flintco is building it. Scott makes the case for why a project of this magnitude and complexity requires a construction manager that delivers like a partner.If you attended the recent grand reopening of Crystal Bridges or are curious about the people and partnerships behind Bentonville's most ambitious projects, this episode of Flintco Talks is for you.

Most industrial property acquisitions include a Phase I Environmental Site Assessment. Many also include a Phase II. But what if some of the biggest environmental liabilities aren't covered by either? In this episode of Tank Talk, Shannon and Haley explore the environmental compliance risks that often go unnoticed during due diligence and why those risks can impact valuation, profitability, financing, insurance, and future operations long after a deal closes. From missing permits and poor recordkeeping to overdue inspections, infrastructure documentation gaps, and compliance history, the team discusses the operational environmental issues that buyers, sellers, lenders, and investors should evaluate before acquiring industrial assets. Whether you're involved in mergers and acquisitions, private equity, commercial lending, or industrial facility operations, this episode provides practical insight into the environmental risks that may not appear in a traditional Phase I or Phase II assessment. Because when it comes to industrial acquisitions, contamination isn't the only environmental liability worth investigating. Support the showintro/outro created with GarageBand

Up next is Part Two of the 2026 Main Camp Recap. We welcome Phase II pick Kamden Kaiser, followed by Phase I picks Jack Hair and Jackson Conroy to the show. The future is bright! Send us Fan MailAsk A Question!Merch Store Official WebsiteFacebookThis recording is the sole view of the members of the Dump & Chase Podcast.  This is a non-commercial fan production. We are not affiliated with or compensated by the Youngstown Phantoms, the United States Hockey League, or any league, club, or team.© 2026 Dump & Chase Podcast. All Rights Reserved

The U.S. government runs a program that will fund your company before you have a single customer — sometimes before you have a finished product at all.It's called SBIR, and in this episode John Martin breaks down exactly how he used it to go from an early-stage idea to a $1.9M U.S. Air Force funding increase, with a shot at a $30M+ award next. If you've got innovative technology and you've ever wondered whether the government would pay you to develop it, this is the conversation to watch.John is the founder of Bundle AR, an augmented reality and XR training platform now used across the Air Force, Space Force, Army, and the commercial world. We get into how SBIR Phase I and Phase II actually work, what TACFI and STRATFI are, why relationships beat writing proposals, and the single mistake most founders make when they try to sell to the government.––––––––––––––––––––––––––––––––––––––CHAPTERS––––––––––––––––––––––––––––––––––––––00:00 The $1.9M the Government Paid Bundle AR00:42 Who Is John Martin & What Bundle AR Does03:33 How He Got His First Government Check05:57 SBIR Explained: Getting Paid for an Idea07:48 Why SBIR Funding Froze (and Just Reopened)09:14 TACFI: The $1.9M Air Force Funding Increase11:54 STRATFI & the New $30M Award for 202616:01 Why Relationships Beat Writing Proposals17:55 How to Win Before the Contract Is Posted22:09 Live Demo: AR Training for the Military28:54 The Smartest Move: Two Revenue Streams29:32 The Truth About SBIR Mills32:24 The GovClose Gauntlet: Rapid Fire37:12 John's Radio Career: Cronkite, Kiss & Taylor Swift38:57 Advice for First-Time Government Contractors41:00 New Markets: Education, Healthcare & School Security44:04 What's Next for Bundle AR––––––––––––––––––––––––––––––––––––––RESOURCES MENTIONED––––––––––––––––––––––––––––––––––––––GovClose Program Overview (free 20-minute training):https://www.govclose.comSBIR / STTR Program (official):https://www.sbir.gov––––––––––––––––––––––––––––––––––––––ABOUT THE GUEST — JOHN MARTIN, BUNDLE AR––––––––––––––––––––––––––––––––––––––John Martin is the founder of Bundle AR (BUNDLAR), a Chicago-basedoperational intelligence platform company. Over 8+ years, Bundle AR hasbuilt a no-code augmented reality and XR-wearable platform that deliverstraining and knowledge "where work happens" for both enterprise and theDepartment of Defense. The company has won SBIR Phase I and Phase II awards,a $1.9M U.S. Air Force Tactical Funding Increase (TACFI), and is nowqualified for a Strategic Funding Increase (STRATFI). Past clients andengagements include Microsoft (Xbox), Thermo Fisher, Cleveland Clinic, theU.S. Air Force, Space Force, Michigan Air National Guard, and the U.S. Army.Learn more / connect with John:Website: https://www.bundlar.comEmail: john@bundlar.comLinkedIn: [paste John's LinkedIn URL here]––––––––––––––––––––––––––––––––––––––ABOUT RICK HOWARD––––––––––––––––––––––––––––––––––––––Rick Howard is a retired USAF Lieutenant Colonel and former DoD acquisitionsofficer who managed over $82 billion in federal contracts. He is the founderof GovClose and the DoD Contract Academy, with 400+ graduates working asgovernment contract consultants, federal account executives, and businessowners winning federal contracts.Get the GovClose Certification: https://www.govclose.com/sales-certification Our students learn the government contracting skills to :1. Start their own consulting business that can earn up to $400k as a "solopreneur" advising businesses that sell to the government.2. Land high paying sales executive jobs with companies in the public sector.3. Increase government contracting revenue for companies selling to the US government.

Falls Prevention After Stroke: What the Latest Research Reveals About Staying Safe and Mobile For many stroke survivors, the fear of falling is a constant companion. It’s there when you get up from the couch, when you navigate the kitchen, when you try to walk further than you did yesterday. That fear is rational, falls after a stroke are common, and their consequences can be serious. But according to Associate Professor Kate Scrivener, a stroke rehabilitation researcher at Macquarie University, that fear doesn’t have to define your recovery. In Episode 409 of the Recovery After Stroke podcast, Kate returns to the show where she first appeared in Episode 257 to discuss her HiWalk walking program and share the results of two major research projects: the published Phase II results of HiWalk, and a new systematic review focused specifically on exercise-based falls prevention after stroke. Who Is Kate Scrivener? Associate Professor Kate Scrivener leads stroke rehabilitation research at Macquarie University in Sydney, Australia. Her work sits at the intersection of real-world clinical practice and rigorous research. She doesn’t just study stroke recovery, she designs and tests the programs that can change it. Kate first appeared on this podcast to talk about HiWalk, a high-dose walking intervention designed to push the limits of what long-term stroke survivors can achieve. Now, with the results published, she’s back to talk about what the data actually showed and what it means for survivors who want to reduce their fall risk. The HiWalk Results: What Happened When 47 Survivors Walked Hard HiWalk was built on a straightforward but ambitious premise: what happens if stroke survivors, who have been living with their disability for years, are given a truly high-dose walking program? Not a gentle weekly session, but 43 hours of structured walking across just three weeks. The Phase II randomized trial enrolled 47 participants and produced results worth paying attention to. Attendance was 91%. Retention was 98%. For a physically demanding trial involving chronic stroke survivors, those numbers are remarkable, and they tell their own story about what survivors are capable of when given a real opportunity. For participants who were not already in active rehabilitation at the time of the trial, walking speed improved by 0.24 metres per second, a clinically significant gain. Self-efficacy, a measure of how confident participants felt in their own ability to walk and function, also improved significantly. The overall group walking speed trend was positive but did not reach statistical significance across the full cohort, partly because HiWalk was a Phase II feasibility trial, designed to test whether the program could be delivered safely and whether participants would complete it. It was not powered to detect large group-wide effects. What it demonstrated is that this kind of high-dose program is feasible, achievable, and produces real gains for the right participants. Why Falls Prevention After Stroke Is Harder Than It Sounds Falls after stroke are not simply a balance problem. They involve fatigue, reduced sensation, spasticity, cognitive changes, and the interaction between all of those things in the unpredictable terrain of daily life. Most stroke survivors are told to be careful. Very few are given a structured, evidence-based program designed specifically to reduce their risk. Kate’s systematic review, published in Clinical Rehabilitation in 2026, searched the global literature for exercise-based trials targeting falls prevention in community-dwelling stroke survivors. Only three trials worldwide met the inclusion criteria. That number alone says something significant. Falls after stroke are widely acknowledged as a major problem. The research base for solving it is thin. Of the three trials identified, exercise trended toward reducing the rate of falls, but the effect on the total number of people who fell was less clear. The standout result came from the FAST trial, which reduced fall rates by 33%. All three qualifying trials were conducted in Australia, raising important questions about whether these findings can be replicated in different healthcare systems with different levels of access to physiotherapy and structured exercise. What This Means for Stroke Survivors Right Now Kate’s research points to two things survivors and their families can act on. First, walking intensity matters. The HiWalk results suggest that long-term survivors who have plateaued in conventional rehabilitation may have more capacity than they or their clinicians assume. High-dose, structured walking appears to produce gains that lower-intensity programs don’t reach. If you’re a survivor who has been told to keep active but hasn’t been given a specific, progressive program, that’s worth a conversation with your physiotherapist. Second, exercise for falls prevention works, but it needs to be the right kind, delivered consistently. Gentle movement is valuable. But the evidence base Kate’s review maps out points toward structured, progressive exercise as the mechanism that shifts fall rates meaningfully. The FAST trial’s 33% reduction didn’t come from telling people to be more careful. It came from changing what they were physically capable of doing. Bill’s book, The Unexpected Way That A Stroke Became The Best Thing That Happened, explores the tools and mindset shifts that underpin a recovery built on action rather than waiting. You can find it at recoveryafterstroke.com/book. The Gap Between Research and Practice One of the most important threads in this conversation is the distance between what the research supports and what most survivors actually receive. Kate’s systematic review found only three qualifying trials globally. HiWalk’s feasibility results are published, but the next step, a large-scale Phase III trial, requires funding, time, and institutional will. For survivors, that gap can feel frustrating. The science is pointing in a clear direction. The programs aren’t yet widely available. Kate’s work is part of closing that distance. Listen to the Full Conversation Episode 409 with Associate Professor Kate Scrivener is available on all major podcast platforms, search Recovery After Stroke and on the Recovery After Stroke YouTube channel. If this show has helped you on your recovery journey, you can support it financially at patreon.com/recoveryafterstroke. This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. The post Walking More, Falling Less – A Researcher’s Mission to Stop Stroke Survivors Hitting the Ground appeared first on Recovery After Stroke.

Why This Episode MattersSabrina Maniscalco is one of the few people in quantum who has lived the full arc: two decades of academic work on open quantum systems and non-Markovian noise at Palermo, Turku, Edinburgh, and Helsinki, followed by founding Algorithmiq with three of her former researchers after an early Qiskit Camp. That trajectory matters now because Algorithmiq just had a landmark stretch — sole winner of the $2M Wellcome Leap Q4Bio prize for a quantum-enabled cancer drug discovery workflow, an €18M Series B, a global HQ move to Milan, and its Tensor Network Error Mitigation (TEM) function landing in IBM's Qiskit Functions catalog.If you're trying to make sense of where quantum software actually creates value before fault tolerance arrives — and what a credible "trajectory to advantage" looks like when paired with real clients in life sciences — this is a grounded, technically specific conversation with someone building it.EPISODE SPONSORThis episode is brought to you by Outshift, Cisco's incubation engine. The need for computational power is rapidly increasing in every sector. From drug discovery to material innovation to complex financial modeling, classical systems are reaching their absolute limits. It's time for a paradigm shift. The answer is a scalable quantum network, built on open standards and vendor-agnostic architecture. By uniting distributed quantum devices, you unlock limitless computational power.Learn more about the Cisco Universal Quantum Switch at Outshift.com.Go deeper with the blog post The switch that quantum networking has been waiting for.What We Get IntoWhy a background in open quantum systems and non-Markovian noise turned out to be unusually well-suited to running algorithms on noisy near-term hardwareThe actual science behind the Q4Bio winning workflow: simulating excited-state dynamics of a photosensitizer drug already in Phase II clinical trials, on up to 100 qubitsHow quantum-boosted DMRG works — and why it gives you a built-in benchmark against the best classical method via the bond dimensionThe tradeoff Sabrina would and wouldn't make between more qubits and lower noise, and why neutral atoms' slower sampling rates matter for chemistryWhy even fault-tolerant algorithms like quantum phase estimation still depend on getting state initialization and measurement rightAlgorithmiq's two-product structure: the Digital Quantum Interface (hardware-agnostic infrastructure) and the life sciences application frameworkHow methods built for chemistry are now opening doors into optimization and GenAI — and why that direction emerged from the work, not from a strategy deckWhat the move from Helsinki to Milan signals about the European quantum ecosystem and Algorithmiq's commercial scale-upHow an active learning pipeline is already proposing novel drug variants for synthesis in Prof. Sherri McFarland's labResources & LinksGuest & CompanyAlgorithmiq — The company Sabrina co-founded with Guillermo García-Pérez, Matteo Rossi, and Boris Sokolov; quantum software for life sciences and chemistry.Sabrina Maniscalco — University of Helsinki Research Portal — Publication record covering open quantum systems, non-Markovian dynamics, and quantum information.Sabrina Maniscalco — AI for Good Bio — Consolidated bio covering academic roles and advisory positions, including IQOQI Austria and CERN's Quantum Technology Initiative.The Q4Bio WinAlgorithmiq Wins $2M Wellcome Leap Q4Bio Prize — Company announcement detailing the photodynamic therapy workflow.Wellcome Leap — Q4Bio Prize Announcement — Funder's perspective on finalists and criteria.IBM Quantum Blog — Q4Bio Finalists — IBM's account of the workflow and quantum-classical integration.Funding & HQ MoveTech.eu — Algorithmiq's €18M Series B and Milan move — Coverage of Italy's largest quantum VC round to date.Quantum Computing Report — Algorithmiq Relocates to Milan — Strategic context including the Q4Bio win and IBM partnership.EU-Startups coverage — Investor lineup and Italy's National Quantum Strategy framing.Quantum Advantage & ToolingIBM Quantum Blog — The Dawn of Quantum Advantage — Includes Algorithmiq's TEM (Tensor Network Error Mitigation) function in the Qiskit Functions catalog.Algorithmiq & IBM Quantum Advantage Tracker — The heterogeneous materials experiment Algorithmiq and IBM put forward as a community benchmark.Silicon Republic interview with Sabrina — Useful prior context on her philosophy of using quantum to simulate quantum systems.Key Quotes & InsightsOn the foundation of the company's approach: "We learned very early what we thought were the bottlenecks of quantum computers — what you really need to worry about if you want to implement computation at scale." A direct line from Qiskit Camp Vermont to Algorithmiq's product strategy.On Q4Bio, in Sabrina's words: "This molecule is already in Phase II clinical trial. So it's not hydrogen. It's a real molecule." A useful counter to the common critique that quantum chemistry demos still live in toy-model land.On quantum-boosted DMRG (insight): In the worst case, the method matches the best classical technique; in the better case, it outperforms it — and the bond dimension tells you which regime you're in. Built-in benchmarking against the classical baseline.On the hardware tradeoff: Asked whether she'd prefer 100 higher-fidelity qubits or 200 noisier ones, Sabrina's answer is "it depends" — and the explanation about why neutral atoms' lower sampling rates limit chemistry use cases is one of the more concrete things you'll hear on platform tradeoffs.On strategy (insight): New verticals at Algorithmiq are ...

What if the most talked-about healing peptide in biohacking came from your own stomach — and carried a risk nobody in the space is talking about?BPC-157, nicknamed "the Wolverine Peptide," has taken over fitness forums, longevity podcasts, and regenerative medicine circles. The preclinical data on tissue repair is remarkable. But the same biological mechanism that drives its healing power is the exact mechanism tumors use to survive and grow.BPC-157 is a synthetic 15 amino acid sequence isolated from human gastric juice, first identified in the early 1990s. It drives tissue repair through six mechanisms: angiogenesis via VEGF upregulation, nitric oxide pathway modulation, FAK paxillin signaling activation, growth hormone receptor upregulation in tendons and ligaments, anti-inflammatory cytokine downregulation, and free radical scavenging for cell protection. An active Phase II randomized controlled trial is currently evaluating BPC-157 for acute hamstring muscle strain repair. Its pro-angiogenic properties raise a theoretical cancer risk in individuals with undiagnosed early-stage tumors. WADA has banned it for competitive athletes. The FDA has reclassified its availability and the FDA Pharmacy Compounding Advisory Committee is reviewing its status on the approved bulk substances list.Dr. Joy Kong talks about:00:00 Meet The Wolverine Peptide02:40 Discovered Inside Human Gastric Juice03:42 Six Pathways That Drive Healing07:33 The First Real Human Trial07:58 Why The FDA Cracked Down09:24 The Hidden Cancer RiskAdditional Resources:✨ Visit My Clinic: Chara Health

On the KMOJ Morning Show, Malik Rucker, founding Executive Director of V3 Sports, joined Freddie Bell for the "Community Builders Series" to discuss his North Minneapolis roots and the experiences that inspired his mission to invest in the community through health, wellness, and opportunity. A fifth-generation Northsider, Rucker reflected on the vision behind V3 Sports and how the organization has grown from a one-person operation into a major nonprofit serving families through fitness, aquatics, youth programming, and education. He explained that V3's mission extends far beyond athletics, focusing on building healthier communities, creating access, and strengthening economic empowerment through intentional partnerships with Northside businesses. Rucker also shared the pride he feels seeing the completed first phase of the V3 Center in action and looked ahead to Phase II, which will bring an Olympic-sized pool and expanded programming to further serve the community. 

We’re starting our read of Tales of Light and Life, a collection of short stories by the authors of the High Republic project. Join us as we discuss transitioning from Phase II to Phase III, Marda Ro sowing the seeds of the Nihil, and the aftermath of the fall of Starlight Beacon. For a list […]

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Power Metallic Mines Inc. (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1)Power Metallic is expanding its summer 2026 exploration program at the Nisk Project in Quebec with three advanced geophysical surveys — SQUIDs, gravity, and Ambient Noise Tomography — designed to pinpoint deeper Ni-Cu-PGE mineralization. These surveys run alongside a 30,000-metre diamond drill program already being mobilized for Q2 and Q3 2026. Investors in the critical metals space should take note as the company systematically targets extensions to the high-grade Lion Zone and new discoveries across the enlarged land package.Minaurum Silver Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M0)Minaurum has reported high-grade drill results from the Europa Sur Vein Zone at the Alamos Silver Project in Sonora, Mexico, highlighted by 3.20 metres of 882 g/t silver equivalent including a peak of 2,423 g/t AgEq over 0.95 metres. Elevated gold and copper values suggest the presence of a high-temperature feeder structure, substantially boosting resource expansion potential within the ongoing 50,000-metre Phase II drill program. Alamos already hosts a 55.4 Moz AgEq inferred resource.Sitka Gold Corp. (TSXV: SIG) (FSE: 1RF) (OTCQX: SITKF)Sitka Gold's first 2026 drill hole at the Blackjack deposit returned 94.0 metres of 1.79 g/t gold including 19.3 metres of 5.04 g/t gold from 1,093 metres depth — the deepest hole ever completed at the RC Gold Project in Yukon. The result extends high-grade gold approximately 370 metres below the existing resource pit and confirms strong continuity with last year's deep discovery. With four rigs active on a fully funded 60,000-metre program, the company is rapidly advancing a district-scale gold system hosting over 5.1 million ounces across indicated and inferred resources.CopAur Minerals Inc. (TSXV: CPAU)CopAur released a Preliminary Economic Assessment and a 52% increase in Mineral Resource Estimate for its Kinsley Mountain Gold Project in Nevada, now totaling 742,000 indicated ounces at 1.11 g/t gold. At the current spot gold price of US$4,500/oz, the project delivers a post-tax NPV of US$147 million and an IRR of 66% with a 1.5-year payback on pre-production CAPEX of US$81.8 million. For a small-cap company with a modest market capitalization, owning 100% of a permitted Nevada heap-leach gold project with these economics represents a potentially significant value proposition.Bottom Line: Today's stories highlight a sector in full motion — high-grade silver and gold drilling campaigns advancing in Mexico and the Yukon, paired with a Nevada gold project delivering compelling PEA economics. Critical metals exploration and near-term gold production potential are the dominant themes.Stay ahead of the market — follow AGORACOM for more breaking small-cap news and insights.

Vikings 2026 Expectations: Rookie Roles, Kyler Murray Fit, and Key Free-Agent Additions — Tyler Forness and Dave Stefano discuss realistic 2026 expectations for the new Minnesota Vikings, focusing on rookies, select UDFAs, and veteran additions. First-round DT Caleb Banks is framed as a long-term play, with year-one goals of staying relatively healthy, playing roughly 500–550 snaps, generating steady pressure, and building consistency. Second-round LB Jake Golday is projected primarily as an off-ball coverage linebacker used in sub-packages while he develops processing and run-fit skills, with caution against labeling him the next Andrew Van Ginkel. They outline modest roles for other picks (including Domonique Orange as a solid nose tackle, limited expectations for Caleb Tiernan and Jakobe Thomas, special-teams emphasis for Max Bredeson and Charles Demmings, skepticism about Demond Claiborne making the roster, and uncertain outlook for seventh-rounder Gavin Gerhardt) and note UDFAs to watch. Among veterans, Kyler Murray is expected to stay healthy and run Kevin O'Connell's offense with more consistency, while James Pierre, Jauan Jennings, and Isaiah Loudermilk are expected to be solid contributors. Timestamps: 00:00 Season Expectations Setup 00:14 Show Intro and Format 01:05 Why Expectations Matter 02:09 QB WR Workouts Note 02:33 Draft Class Kickoff 02:49 Caleb Banks Outlook 07:58 Jake Golday Role Debate 21:34 Domonique Orange Projection 23:34 Other Third Rounders 25:34 Jakobe Thomas and Safety Room 27:39 Harrison Smith Return Talk 30:04 Day Three Picks Begin 30:44 Fullback Role Unknown 31:48 Can Bredeson Win Job 33:05 No Friends Drafting 34:14 Demmings Development Plan 35:12 Claiborne Roster Doubts 40:44 Late Picks And UDFAs 41:49 Punter Battle And Cap 42:30 Kyler Murray Expectations 45:05 Fixing Explosives Vs Consistency 49:05 Free Agents Pierre Jennings 52:19 Loudermilk Camp Fit 53:49 Wrap Up And Schedule _______________________ ⭐️ Subscribe to us here! - https://www.youtube.com/@vikings1stskol92 ⭐️ Our Twitter can be found at @Vikings1stSKOL ⭐️ Our Discord at https://discord.com/invite/493z6mQXcN ⭐️ Tyler Forness can be read at A to Z Sports - https://atozsports.com/nfl/minnesota-vikings-news/ ⭐️ Submit questions: forms.gle/7LJkCAern9kdUkuD8 ⭐️ On Facebook - https://www.facebook.com/vikings1standskol ⭐️ Watch the live show here: https://youtu.be/-cl_KEGFuws Fan With Us!!! Tyler Forness @TheRealForno of Vikings 1st & SKOL @Vikings1stSKOL and A to Z Sports @AtoZSportsNFL, with Dave Stefano @Luft_Krigare producing this Vikings 1st & SKOL production, the @RealFornoShow. Podcasts partnered with Fans First Sports Network @FansFirstSN. Learn more about your ad choices. Visit megaphone.fm/adchoices

Vikings 2026 Expectations: Rookie Roles, Kyler Murray Fit, and Key Free-Agent Additions — Tyler Forness and Dave Stefano discuss realistic 2026 expectations for the new Minnesota Vikings, focusing on rookies, select UDFAs, and veteran additions. First-round DT Caleb Banks is framed as a long-term play, with year-one goals of staying relatively healthy, playing roughly 500–550 snaps, generating steady pressure, and building consistency. Second-round LB Jake Golday is projected primarily as an off-ball coverage linebacker used in sub-packages while he develops processing and run-fit skills, with caution against labeling him the next Andrew Van Ginkel. They outline modest roles for other picks (including Domonique Orange as a solid nose tackle, limited expectations for Caleb Tiernan and Jakobe Thomas, special-teams emphasis for Max Bredeson and Charles Demmings, skepticism about Demond Claiborne making the roster, and uncertain outlook for seventh-rounder Gavin Gerhardt) and note UDFAs to watch. Among veterans, Kyler Murray is expected to stay healthy and run Kevin O'Connell's offense with more consistency, while James Pierre, Jauan Jennings, and Isaiah Loudermilk are expected to be solid contributors. Timestamps: 00:00 Season Expectations Setup 00:14 Show Intro and Format 01:05 Why Expectations Matter 02:09 QB WR Workouts Note 02:33 Draft Class Kickoff 02:49 Caleb Banks Outlook 07:58 Jake Golday Role Debate 21:34 Domonique Orange Projection 23:34 Other Third Rounders 25:34 Jakobe Thomas and Safety Room 27:39 Harrison Smith Return Talk 30:04 Day Three Picks Begin 30:44 Fullback Role Unknown 31:48 Can Bredeson Win Job 33:05 No Friends Drafting 34:14 Demmings Development Plan 35:12 Claiborne Roster Doubts 40:44 Late Picks And UDFAs 41:49 Punter Battle And Cap 42:30 Kyler Murray Expectations 45:05 Fixing Explosives Vs Consistency 49:05 Free Agents Pierre Jennings 52:19 Loudermilk Camp Fit 53:49 Wrap Up And Schedule _______________________ ⭐️ Subscribe to us here! - https://www.youtube.com/@vikings1stskol92 ⭐️ Our Twitter can be found at @Vikings1stSKOL ⭐️ Our Discord at https://discord.com/invite/493z6mQXcN ⭐️ Tyler Forness can be read at A to Z Sports - https://atozsports.com/nfl/minnesota-vikings-news/ ⭐️ Submit questions: forms.gle/7LJkCAern9kdUkuD8 ⭐️ On Facebook - https://www.facebook.com/vikings1standskol ⭐️ Watch the live show here: https://youtu.be/-cl_KEGFuws Fan With Us!!! Tyler Forness @TheRealForno of Vikings 1st & SKOL @Vikings1stSKOL and A to Z Sports @AtoZSportsNFL, with Dave Stefano @Luft_Krigare producing this Vikings 1st & SKOL production, the @RealFornoShow. Podcasts partnered with Fans First Sports Network @FansFirstSN. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of BioTalk with Rich Bendis, Sam Gussman-Toh, Portfolio Manager for the Small Business Program at ARPA-H, joins the conversation to discuss how the agency is creating new pathways for small businesses developing ambitious health technologies. Sam explains how the ARPA-H model differs from traditional federal funding programs, with a focus on moonshot health solutions, program manager-led portfolios, milestone-driven contracts, and a strong emphasis on moving technologies toward real-world use. He also discusses how the Small Business Program supports SBIR and STTR performers through Phase I, Phase II, Direct to Phase II, and Fast Track awards. The conversation highlights how ARPA-H is working with ambitious small businesses, including non-traditional companies and early-stage startups that may be working with the federal government for the first time. Sam also shares how commercialization support is built into the program, including ARPA-H's Entrepreneur-in-Residence partnership with BioHealth Innovation. Through that relationship, BHI EIRs help performers strengthen regulatory strategy, intellectual property planning, go-to-market strategy, reimbursement considerations, and other key commercialization needs. Sam also discusses ARPA-H's draft Small Business Program solicitation, the upcoming virtual Proposers' Day on June 11, and what companies should know about the application process, topic areas, technical pitches, and future funding opportunities. Editing and post-production work for this episode was provided by The Podcast Consultant. Sam Gussman-Toh is Portfolio Manager for the Small Business Program at ARPA-H, where he coordinates and oversees the agency's SBIR/STTR awards and commercialization support services for participating small businesses. Sam joined ARPA-H in 2022 and wrote the agency's first SBIR/STTR solicitation. He has held several roles in the Office of Commercialization and has worked closely with Program Managers to build the agency's commercialization infrastructure and strategy. Previously, Sam designed and managed rapid prototyping programs across agencies in the Department of War. His technical background is in computer science, with interests in computer vision, autonomous robotic systems, and computational pathology.

Acute respiratory distress syndrome (ARDS) induced by COVID-19 was a leading cause of severe illness and death during the pandemic, driven by an intense innate immune response, hyperinflammation, and a decrease in lymphocytes. Mesenchymal stromal cells (MSCs) represent a potential therapeutic option for ARDS due to their ability to modulate the immune system and inflammation. Our guests report results from a Health Canada–regulated Phase I and Phase II trials evaluating freshly cultured umbilical cord–derived MSCs in patients with COVID-19-related ARDS, including assessments of safety, maximum feasible tolerated dose, and preliminary efficacy. Their work explores a therapeutic strategy to improve ARDS outcomes using MSCs, which will be important for optimizing and targeting future cellular therapies.GuestDuncan Stewart, MD, Ottawa Hospital Research Institute and University of Ottawa, CanadaElmira Safaie Qamsari, Ottawa Hospital Research Institute, CanadaHostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting DocumentsPaper link: Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials About Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. X: @StemCellReportsAbout ISSCRAcross more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.ISSCR StaffKeith Alm, Shuangshuang Du, Kym Kilbourne, Megan Koch, Jack Mosher, and Hunter Reed

JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT

As cancer vaccines move into Phase II and III clinical trials, it isincreasingly important for surgeons to understand their role in thisevolving landscape. What exactly are these vaccines, how do they work,and what should the surgical community know about theirimplementation? Join BTK surgical education fellows Kara Button andMichelle LaBella as they sit down with Professor Robert Jones to breakdown the science of mRNA vaccines, the logistics of tissueprocurement, and the future of cancer care.Hosts:- Professor Robert Jones: Consultant Liver Surgeon, Liverpool UniversityHospitals; UK National Institute for Healthcare Research, Co-Lead forthe Cancer Vaccine Innovation Pathway, Bowel Cancer UK and RoyalCollege of Surgeons UK Lead for Research into Advanced Bowel Cancer,and UK Chief Investigator for the BNT122-01 trial.https://www.linkedin.com/in/robert-jones-6103722a/- Kara Button, DO: General Surgery Resident, Maine Medical Center;Behind the Knife Surgical Education Fellow.- Michelle LaBella, MD: General Surgery Resident; University of NorthCarolina; Behind the Knife Surgical Education Fellow.References:https://clinicaltrials.biontech.com/trials/BNT122-01Jones RP, Lee LYW, Corrie PG, et al. Individualized cancer vaccinesversus surveillance after adjuvant chemotherapy for surgicallyresected high-risk stage 2 and stage 3 colorectal cancer: protocol fora randomized trial. BJS. 2023;110(12):1883-1884.doi:10.1093/bjs/znad332https://pubmed.ncbi.nlm.nih.gov/37856683/Tie J, Wang Y, Loree JM, et al. Circulating tumor DNA-guided adjuvanttherapy in locally advanced colon cancer: the randomized phase 2/3DYNAMIC-III trial. Nat Med. 2025;31(12):4291-4300.doi:10.1038/s41591-025-04030-whttps://pubmed.ncbi.nlm.nih.gov/41115959/Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigenvaccines stimulate T cells in pancreatic cancer. Nature.2023;618(7963):144-150. doi:10.1038/s41586-023-06063-yhttps://pubmed.ncbi.nlm.nih.gov/37165196/https://www.cancer.ox.ac.uk/research/lynchvax#:~:text=The%20LynchVax%20program%2C%20funded%20by,individuals%20with%20this%20genetic%20conditionPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

João Canêdo of Fenix Gold, own and operated by Rio2, joins Trevor for an MSD interview following last week's site visit to the Fenix Gold Project. João provides a thorough update on the mine's construction, which is close to complete. The company has produced dore leading up to its full commissioning. But Fenix continues to think long-term with the strategy of a Phase II. He walks us through those ideas of how to truly optimize the mine plan.

Big Breaking! Opinion Poll Gives Clear Majority to BJP | 60/142 in Phase II, 154/294 Overall

Pancreatic cancer remains one of the most difficult cancers to treat, largely because its dense tumor microenvironment makes it difficult for chemotherapy drugs to reach their target. This often leads to poor patient outcomes and underscores the urgent need for new therapeutic strategies to overcome these barriers. In this episode of Curing with Sound, Jae Young Lee, MD, PhD, professor and researcher at Seoul National University Hospital, shares his work exploring focused ultrasound as a noninvasive treatment option for pancreatic cancer. He explains how this technology creates subtle mechanical stress within the tumor, helping to open up its structure so chemotherapy can work more effectively. Dr. Lee also shares encouraging results from his Phase II clinical trial and looks ahead to a pivotal Phase III study, offering new hope for improving patient outcomes. Discussion highlights: A New Treatment Strategy: Focused ultrasound technology shows promise for addressing the unique challenges of pancreatic cancer, enabling precise tumor targeting while preserving critical surrounding structures. From Research to Reality: Learn how Seoul National University Hospital, a designated Focused Ultrasound Center of Excellence, is integrating this technology into clinical care while advancing research across oncology, neurosurgery, and pain management. Seoul National University Hospital Website EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/    

This week, we’re wrapping up Path of Vengeance by Cavan Scott and discussing the manga Edge of Balance: Precedent. Join us as we discuss Marda’s character arc, transitioning into Phase III of the High Republic project, and our feelings about Phase II overall. For a list of Black-owned bookstores to order from, now and always, […]

What if one of the most powerful tools for detoxification, brain health, hormone balance, and healthy aging was something you could grow in your kitchen? In this science-packed episode of The Girlfriend Doctor Podcast, Dr. Anna Cabeca sits down with renowned nutritional biochemist Dr. Jed W. Fahey — the pioneering researcher behind the discovery of the extraordinary chemoprotective power of broccoli sprouts. After 27 years at Johns Hopkins University School of Medicine, where he directed the Cullman Chemoprotection Center, Dr. Fahey explains why sulforaphane — derived from glucoraphanin found abundantly in broccoli sprouts — activates your body's own protective systems at the cellular level. Dr. Anna shares her personal clinical experiences using sulforaphane-rich compounds to support detoxification pathways, immune resilience, abnormal Pap smears, skin health, neurocognitive protection, and hormone balance — especially in midlife women. In this episode, you'll learn: What sulforaphane actually is (and why it matters) How it activates phase II detoxification pathways Why broccoli sprouts are more potent than mature broccoli Neuroprotective and brain benefits Research around skin and melanoma protection Dosage guidance for sprouts vs. supplements How to safely incorporate them into your daily routine This isn't about trendy superfoods. It's about turning on your body's built-in defense systems. Small daily choices. Powerful cellular protection.   Key Timestamps 00:01 – Welcome & why broccoli sprouts matter 03:14 – Broccoli sprouts vs. mature broccoli: what's the difference? 06:21 – What exactly is sulforaphane? 09:24 – Phase II detoxification explained simply 15:23 – Dr. Anna's powerful clinical case using sulforaphane 17:31 – Brain health & neurocognitive benefits 24:43 – How much should you take daily? 31:24 – Skin health & melanoma research 33:35 – Food vs. supplement: dosage considerations 42:13 – One big takeaway for healthy aging   Memorable Quotes "This isn't about complicated science. It's about small daily choices that protect your cells." "Sulforaphane switches on your body's own protective systems." "Broccoli sprouts are foundational — not optional — for longevity." "We want to help and do no harm." "You were made for vitality."   Connect With Our Guest Dr. Jed W. Fahey

What will Phase II of Trump's plan for Gaza look like on the ground? Who's  in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing structure — Trump's “Board of Peace,” the Gaza Executive Committee, a Palestinian technocrat government, and an International Stability Force — and explain what will actually matter on the ground: money, security control, and whether Hamas truly disarms. They also assess Israel–U.S. friction, the odds of renewed fighting, what daily life in Gaza looks like right now, and how all of this collides with Israeli election politics.In this episode...- Understanding the Governance of Gaza- Who Holds Power in Gaza? Money, Security, and Accountability- Hamas After the War- Phase Two, the Yellow Line, and Israeli Withdrawal- The International Stability Force Explained- Life in Gaza Right Now- Gaza Meets Israeli Politics- The Bigger Regional PictureFrom the episode:This episode was sponsored by The Shalom Hartman Institute: Learn more about the Community Leadership Program at https://go.hartman.org.il/CLP-CMBMore Ark Media:Want to join Ark Media? Check out our careers page for new openings.Subscribe to Inside Call me BackListen to For Heaven's SakeListen to What's Your Number?Watch Call me Back on YouTubeNewsletters | Ark Media | Amit Segal | Nadav EyalInstagram | Ark Media | DanX | DanDan Senor & Saul Singer's book, The Genius of IsraelGet in touchCredits: Ilan Benatar, Adaam James Levin-Areddy, Brittany Cohen, Martin Huergo, Mariangeles Burgos, and Patricio Spadavecchia, Yuval Semo 

Tinnitus isn't just a ringing in your ears — it can interfere with memory, mood, and sleep, affecting your overall well-being when left unmanaged A Phase II clinical trial found that low-intensity sound therapy (LINTS) can reduce tinnitus symptoms without blocking out real-world sounds, helping the brain tune out the ringing naturally Sound therapy works by helping your brain reclassify tinnitus as background noise, reducing its emotional and cognitive impact over time For best results, work with a professional — sound therapy is most effective when guided by a trained audiologist Supporting your body with antioxidant-rich foods, magnesium, deep sleep, and a low-stress lifestyle can also reduce tinnitus intensity and help protect your hearing

This week on the Mark Levin Show, On Monday's Mark Levin Show, 7 million old hippies turned out in the Democrat-Marxist-Islamist No Kings mini-parades on Saturday? Well, 330 million Americans did not. The tea party movements had massive rallies, and it wasn't just one day. How is this President a king? He's working through the courts when he's blocked on improving America. For example, in a victory for America the 9th Circuit court ruled that the National Guard can be deployed in Portland. Also, Democrats turned a continuing resolution into a government shutdown blackmail threat to reverse provisions of the big, beautiful bill. Later, Marxist-Islamist Zohran Mamdani is pro-terrorism - from his associations with Imam Siraj Wahaj, his support for Hamas, his calls to globalize the Intifada, and his ties to the Qatar royal family. If people in NYC vote for Mamdani, they are voting for somebody who embraces terrorists, terrorist organizations, and hence, by implication, terrorism. Mamdani is no moderate, he's a grave threat to the people in New York City. Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy, and massive government spending to control the people. Later, Zohran Mamdani got his butt kicked at the NYC debate. He's a sloganeer, which is typical of Marxists, but he won't be substantive at all. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices